Profit outpacing revenue
Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.
Importance 64 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.
Importance 64 / 95 · growth
ROE of 21.5% is the highest in 4 years (prior range 13.5% to 18.8%).
Importance 56 / 95 · profitability
Revenue compounded at 14.5% a year over 4 years (₹14,663 → ₹25,229).
Importance 55 / 95 · growth
Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.
Peer set used on this page: 3 hospital.
Revenue grew 11.2% a year over 4 years, from ₹6,098 cr in FY2022 to ₹9,326 cr in FY2026. Net profit grew 22.4% a year over the same period.
Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Revenue compounded at 14.5% a year over 4 years (₹14,663 → ₹25,229).
Net profit grew 33.1% year on year (FY2025 → FY2026).
Revenue grew 15.8% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,615 cr (up 20.8% on the same quarter last year) and net profit ₹660 cr (up 33.5%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹660 cr, up 33.5% from ₹494 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 revenue was ₹7,615 cr, up 20.8% from ₹6,304 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 EBIT was ₹1,005 cr, up 29.2% from ₹778 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 5,527 | +13.9% | 379 | +49.1% | 6.9% |
| Q4 FY25 | 5,592 | +13.1% | 415 | +60.4% | 7.4% |
| Q1 FY26 | 5,842 | +14.9% | 441 | +39.8% | 7.5% |
| Q2 FY26 | 6,304 | +12.8% | 494 | +24.8% | 7.8% |
| Q3 FY26 | 6,477 | +17.2% | 516 | +36.1% | 8.0% |
| Q4 FY26 | 6,606 | +18.1% | 551 | +33.0% | 8.3% |
| Q1 FY27 | 7,044 | +20.6% | 610 | +38.4% | 8.7% |
| Q2 FY27 | 7,615 | +20.8% | 660 | +33.5% | 8.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 28.9% in FY2026, against 24.0% in FY2022. ROE was 16.0% and ROCE 19.7% in FY2026.
ROE of 21.5% is the highest in 4 years (prior range 13.5% to 18.8%).
Rule ROE_AT_MULTI_YEAR_HIGH
ROE of 21.5% is well above the hospital median of 14.3%.
EBITDA margin of 15.7% is below the hospital median of 23.4%.
ROE improved from 18.8% to 21.5% year on year.
Debt-to-equity was 0.18x in FY2026, against 0.33x in FY2022; interest coverage 9.10x. Operating cash flow was 1.38x net profit.
Net worth compounded at 14.0% a year over 4 years (₹5,899 → ₹9,975).
Rule NET_WORTH_COMPOUNDING
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.43×).
Free cash flow has been positive in 5 of the last 5 years.
Within its 3-company Hospital peer group, it ranks 1 of 3 on return on equity and 3 of 3 on EBITDA margin. Its P/E of 56.5 compares with a peer median of 58.7.
Ranked against 3 hospital (FY2026, consolidated). No peer-relative rule fired for this company.
APOLLOHOSP · 3rd of 3 · set median 17.3%
APOLLOHOSP · 3rd of 3 · set median 23.4%
APOLLOHOSP · 1st of 3 · set median 14.3%
APOLLOHOSP · 1st of 3 · set median 58.7×
On the trailing twelve months. Last full year: P/E 66.0× · P/S 5.2× · ROE 21.5%. TTM and full-year profit differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 23.8% over 1 year, up 68.1% over 3 years (18.9% a year) and up 64.4% over 5 years (10.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is at its 52-week high.
Over 4 years profit (15.9% a year) and the stock (18.9% a year) compounded at roughly the same rate.
Rule STOCK_TRACKED_EARNINGS
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6,098 | 6,525 | 7,274 | 8,202 | 9,326 |
| Total income | 6,145 | 6,676 | 7,454 | 8,550 | 9,698 |
| EBITDA | 1,466 | 1,833 | 1,977 | 2,392 | 2,700 |
| Profit before tax | 852 | 1,228 | 1,329 | 1,689 | 1,946 |
| Net profit | 665 | 1,085 | 1,011 | 1,296 | 1,493 |
| EPS (₹) | 46.3 | 75.5 | 70.3 | 180.3 | 103.8 |
| Net worth | 6,111 | 6,925 | 7,711 | 8,734 | 9,963 |
| Total debt | 2,024 | 1,761 | 1,956 | 1,783 | 1,822 |
| Operating cash flow | 1,201 | 1,224 | 1,191 | 1,742 | 2,059 |
| Free cash flow | 743 | 831 | 572 | 897 | 1,019 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 7.0 | 11.5 | 12.8 | 13.7 |
| Profit growth YoY | — | 63.1 | -6.8 | 28.3 | 15.1 |
| Profitability | |||||
| EBITDA margin % | 24.0 | 28.1 | 27.2 | 29.2 | 28.9 |
| Net margin % | 10.8 | 16.2 | 13.6 | 15.2 | 15.4 |
| Return on equity % | 10.9 | 16.6 | 13.8 | 15.8 | 16.0 |
| Return on capital % | 13.6 | 17.4 | 17.2 | 19.2 | 19.7 |
| Leverage & cash | |||||
| Debt to equity | 0.33 | 0.25 | 0.25 | 0.20 | 0.18 |
| Cash flow ÷ profit | 1.81 | 1.13 | 1.18 | 1.34 | 1.38 |
| Current ratio | 2.91 | 2.53 | 2.68 | 2.44 | 1.74 |